CA19-9 Pancreatic Cancer Antigen

£149

CA 19-9 is most appropriately used in monitoring disease progression or effectiveness of treatment once diagnosis of the tumour has been made and serum concentrations have been shown to be raised prior to treatment (Lewis negative individuals do not express CA 19-9).

CA 19-9 has been shown to be raised in:

Pancreatic adenoncarcinomas (most)
Gastric carcinomas (50%)
Colorectal carcinomas (30%)

CA 19-9 should not be used for non-GIT malignancy.

Biomarkers:

CA19-9

Turnaround time:

7 Working Days

Note:

This service is only available to the age of 16 and above.

Furthermore, Any Cancellation within 48 hours prior to appointment will incur a charge of 20% of total service cost.